This finding is in line with earlier observations where a combination of MDV3100 with CH5132799 (an AKT inhibitor) was shown to be effective in delaying resistance development in preclinical models of PCa [26, 27]. This evidence concerns the gene AKT1 and posterior cortical atrophy.